Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New lung nodule marking method could replace CT-Guided technique

NCT ID NCT06957600

Knowledge-focused Sponsor: Semmelweis University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed trial with 66 participants compared two methods for marking small lung nodules before minimally invasive surgery: navigational bronchoscopy using a green dye (ICG) and CT-guided radioisotope injection. The goal was to see which method helps surgeons find and remove nodules faster and more completely. Researchers also checked for complications and surgeon satisfaction. Results could guide which technique is safer and more effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Preoperative marking (navigational bronchoscopy with ICG dye or CT-guided radioisotope)
What this could lead to
If successful, this could show that navigational bronchoscopy is a safer, radiation-free alternative for marking lung nodules before surgery, potentially improving surgical outcomes.
What could go wrong
This is a small, completed trial with only 66 participants, so results may not apply to all patients. Both methods are already in use, so no major breakthrough is expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

66 people

The number who actually took part.

Started

Jun 2025

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

In this study, patients with lung nodules between 10 and 30 mm (under clinical IC or lower stage if it was a case of NSCLC) who are fit for surgery will be enrolled. The investigators will collect epidemiological data, including age, race, gender, Charlson Comorbidity Index, smoking history, medications taken, previous surgeries, significant diseases, BMI, and detailed parameters of the radiological size of the tumor preoperatively. Within two months before surgery, the investigators will conduct a contrast-enhanced chest CT, which will include the upper abdomen and lung function tests (FVC, FEV1, DLCO). Patients who had previous thoracic surgery, are under 18 or over 85 years of age, or have FVC or FEV1 less than 60% will be excluded. Any patient unsuitable for the complete preoperative diagnostic procedure will also be excluded (for example, where contrast material is contraindicated in chronic kidney failure). Pathological parameters of the lesion will be evaluated within four weeks after surgery. Imaging will be conducted at least during the one-month follow-up to monitor complications. Summary: Inclusion Criteria: * Aged from 18 to 85 * 1-3 cm lung nodules * planned procedure VATS uniportal diagnostic wedge Exclusion Criteria: * Previous thoracic surgery * CCI greater than 12 * Long-term steroid treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Icg (indocyanine green) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung neoplasm Margins of Excision virus-associated trichodysplasia spinulosa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Icg (indocyanine green) LUNG VATS

Contacts and locations

Locations

  • Semmelweis University- National Institute of Oncology Department of Thoracic Surgery

    Budapest, Budapest, 1122, Hungary

More trials for these conditions

Other studies related to the condition(s) this trial covers.